MC

530.3

+7.21%↑

SANES

6.742

+1.63%↑

BNP

79.04

+2.21%↑

DB1.DE

279.4

-3.39%↓

CABK

7.336

+1.21%↑

MC

530.3

+7.21%↑

SANES

6.742

+1.63%↑

BNP

79.04

+2.21%↑

DB1.DE

279.4

-3.39%↓

CABK

7.336

+1.21%↑

MC

530.3

+7.21%↑

SANES

6.742

+1.63%↑

BNP

79.04

+2.21%↑

DB1.DE

279.4

-3.39%↓

CABK

7.336

+1.21%↑

MC

530.3

+7.21%↑

SANES

6.742

+1.63%↑

BNP

79.04

+2.21%↑

DB1.DE

279.4

-3.39%↓

CABK

7.336

+1.21%↑

MC

530.3

+7.21%↑

SANES

6.742

+1.63%↑

BNP

79.04

+2.21%↑

DB1.DE

279.4

-3.39%↓

CABK

7.336

+1.21%↑

Search

Sartorius Stedim Biotech.

Slēgts

SektorsFinanšu

203.1 0.64

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

196.55

Max

203.6

Galvenie mērījumi

By Trading Economics

Ienākumi

75M

115M

Pārdošana

-6.7M

745M

P/E

Sektora vidējais

100.566

24.507

EPS

1.16

Dividenžu ienesīgums

0.33

Peļņas marža

15.498

Darbinieki

9,961

EBITDA

124M

256M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+18.09% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.33%

4.35%

Nākamie ieņēmumi

2025. g. 22. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

4.2B

21B

Iepriekšējā atvēršanas cena

202.46

Iepriekšējā slēgšanas cena

203.1

Ziņu noskaņojums

By Acuity

34%

66%

93 / 540 Rangs Finance

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Sartorius Stedim Biotech. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. maijs 23:48 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

2025. g. 11. maijs 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

2025. g. 11. maijs 23:45 UTC

Tirgus saruna

Oil Rises Amid Improved Market Mood -- Market Talk

2025. g. 11. maijs 23:38 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Aristocrat Has Significant Firepower for M&A -- Market Talk

2025. g. 11. maijs 23:36 UTC

Tirgus saruna

Global Markets Uncertain About US-China Trade News -- Market Talk

2025. g. 11. maijs 23:35 UTC

Tirgus saruna

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

2025. g. 11. maijs 23:33 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

2025. g. 11. maijs 23:32 UTC

Top Ziņas

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

2025. g. 11. maijs 22:44 UTC

Tirgus saruna

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

2025. g. 11. maijs 22:33 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

2025. g. 11. maijs 20:19 UTC

Top Ziņas

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

2025. g. 11. maijs 16:00 UTC

Top Ziņas

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

2025. g. 11. maijs 11:00 UTC

Top Ziņas

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

2025. g. 11. maijs 08:00 UTC

Top Ziņas

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

2025. g. 11. maijs 01:00 UTC

Top Ziņas

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

2025. g. 11. maijs 01:00 UTC

Top Ziņas

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

2025. g. 10. maijs 21:54 UTC

Top Ziņas

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

2025. g. 10. maijs 17:12 UTC

Top Ziņas

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

2025. g. 10. maijs 15:41 UTC

Top Ziņas

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

2025. g. 10. maijs 12:00 UTC

Top Ziņas

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

2025. g. 10. maijs 09:30 UTC

Top Ziņas

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

2025. g. 10. maijs 08:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 10. maijs 03:52 UTC

Top Ziņas

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

2025. g. 9. maijs 23:51 UTC

Iegādes, apvienošanās, pārņemšana

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

2025. g. 9. maijs 22:06 UTC

Tirgus saruna

Arm Holdings Remains a Strong Growth Story -- Market Talk

2025. g. 9. maijs 21:37 UTC

Top Ziņas

U.S. Sets August Deadline for Debt Ceiling -- WSJ

2025. g. 9. maijs 21:10 UTC

Top Ziņas

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

2025. g. 9. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 9. maijs 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 9. maijs 20:42 UTC

Top Ziņas

Stocks Get a Break From Trade Chaos -- WSJ

Salīdzinājums

Cenas izmaiņa

Sartorius Stedim Biotech. Prognoze

Cenas mērķis

By TipRanks

18.09% augšup

Prognoze 12 mēnešiem

Vidējais 239.13 EUR  18.09%

Augstākais 250 EUR

Zemākais 210 EUR

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sartorius Stedim Biotech. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

5

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

202.7 / 211.7Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

93 / 540 Rangs Finanšu

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.